NCCM
SLS icon

Nine Chapters Capital Management’s SELLAS Life Sciences SLS Stock Holding History

Nine Chapters Capital Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14
Closed -$13K – 156
2017
Q1 		$13K Buy
+14
New +$23.2K 0.02% 235

Other funds holding SLS

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nine Chapters Capital Management's SLS Position: Q2 2017 in Review

Nine Chapters Capital Management sold out of SELLAS Life Sciences (SLS) in Q2 2017, closing a stake of 14 shares — an estimated $13K sold.

Nine Chapters Capital Management first reported a position in SLS in Q1 2017 and held it in 1 quarter. The position peaked at $13K in Q1 2017. 34 funds tracked by Wall St. Rank hold SLS as of Q2 2017.

  • Nine Chapters Capital Management reported no remaining SELLAS Life Sciences position as of Q2 2017 after selling out during the quarter.
  • Nine Chapters Capital Management sold 14 SELLAS Life Sciences shares in Q2 2017, an estimated $13K.
  • Nine Chapters Capital Management first reported a position in SELLAS Life Sciences in Q1 2017 and held it in 1 quarter.
  • Nine Chapters Capital Management's SELLAS Life Sciences position peaked at $13K in Q1 2017.
  • 34 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2017.

Based on Nine Chapters Capital Management's 13F filing for Q2 2017, filed 31 Jul 2017.